Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Fig. 2

Change from baseline to cycle 2, day 1 in EQ-5D-5 L VAS and EORTC QLQ-C30 measures. Mean change from baseline to C2D1 in the EQ-5D-5 L VAS (A), EORTC QLQ-C30 physical function (A), EORTC QLQ-C30 role function (A), EORTC QLQ-C30 overall health (B), and EORTC QLQ-C30 quality of life (B). P-values are nominal, and no statistical significance is being claimed. The Physical and Role Function questions were rolled up to a score out of 100; questions C29 and C30 are based on 7-point scales. C2D1, cycle 2, day 1; EORTC QLQ-C30, European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D-5 L, EuroQoL 5-Dimension 5-Level; VAS, visual analogue scale

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us